Literature DB >> 22763818

Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells.

Lifeng Feng1, Min Pan, Jie Sun, Haiqi Lu, Qi Shen, Shengjie Zhang, Tingting Jiang, Liangyi Liu, Wei Jin, Yan Chen, Xian Wang, Hongchuan Jin.   

Abstract

During cancer development, tumor suppressor genes were silenced by promoter methylation or histone deacetylation. Histone deacetylases (HDACs) are important to maintain histone deacetylation. HDAC inhibitors (HDACis) were thus proposed as a new therapeutic approach to cancer. The current study aims to understand the effect and molecular mechanisms of HDACis on gastric cancer cells. Trichostatin A (TSA) significantly inhibited the growth of gastric cancer cells by inducing apoptosis. Gene profiling results showed PUMA (p53 upregulated modulator of apoptosis) as one of 122 genes upregulated in TSA-treated gastric cancer cells. PUMA was downregulated in gastric cancer cell lines and primary gastric carcinoma tissues. Patients with low PUMA expression had significant decreases in overall survival (HR, 2.04; p = 0.047). Ectopic PUMA expression inhibited the growth of gastric cancer cells while PUMA depletion promoted cellular growth. The knockdown of HDAC3 but not other HDACs upregulated PUMA expression. HDAC3 could bind to PUMA promoter, which was abrogated after TSA treatment. In contrast to TSA and SB, HDAC3 siRNA failed to upregulate p53 expression but promoted the interaction of p53 with PUMA promoter. In summary, proapoptotic PUMA was downregulated in gastric cancer and its mRNA expression level is a valuable prognosis factor for gastric cancer. HDAC3 is important to downregulate PUMA expression in gastric cancer and HDACis, like TSA, promoted PUMA expression through stabilizing p53 in addition to HDAC3 inhibition. In combination with chemotherapy, targeting HDAC3 might be a promising strategy to induce apoptosis of gastric cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763818     DOI: 10.1007/s00109-012-0932-x

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  26 in total

1.  PUMA induces the rapid apoptosis of colorectal cancer cells.

Authors:  J Yu; L Zhang; P M Hwang; K W Kinzler; B Vogelstein
Journal:  Mol Cell       Date:  2001-03       Impact factor: 17.970

2.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways.

Authors:  John R Jeffers; Evan Parganas; Youngsoo Lee; Chunying Yang; JinLing Wang; Jennifer Brennan; Kirsteen H MacLean; Jiawen Han; Thomas Chittenden; James N Ihle; Peter J McKinnon; John L Cleveland; Gerard P Zambetti
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

3.  PUMA couples the nuclear and cytoplasmic proapoptotic function of p53.

Authors:  Jerry E Chipuk; Lisa Bouchier-Hayes; Tomomi Kuwana; Donald D Newmeyer; Douglas R Green
Journal:  Science       Date:  2005-09-09       Impact factor: 47.728

Review 4.  Epigenetics in cancer.

Authors:  Manel Esteller
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 5.  Isoform-selective histone deacetylase inhibitors.

Authors:  Yukihiro Itoh; Takayoshi Suzuki; Naoki Miyata
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

6.  Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.

Authors:  Hyun-Jung Kim; Suk-Chul Bae
Journal:  Am J Transl Res       Date:  2010-12-26       Impact factor: 4.060

7.  Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.

Authors:  Xiaotian Zhang; Masakazu Yashiro; Jun Ren; Kosei Hirakawa
Journal:  Oncol Rep       Date:  2006-09       Impact factor: 3.906

8.  p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion.

Authors:  Bin Wu; Wei Qiu; Peng Wang; Hui Yu; Tao Cheng; Gerard P Zambetti; Lin Zhang; Jian Yu
Journal:  Gut       Date:  2006-11-24       Impact factor: 23.059

9.  Effects of trichostatin A, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.

Authors:  Hyeyoung Park; Young Jun Lee; Tae Hyung Kim; Jaewon Lee; Sungpil Yoon; Wahn Soo Choi; Chang-Seon Myung; Hyung Sik Kim
Journal:  Int J Mol Med       Date:  2008-11       Impact factor: 4.101

10.  Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer.

Authors:  Toshiro Obata; Minoru Toyota; Ayumi Satoh; Yasushi Sasaki; Kazuhiro Ogi; Kimishige Akino; Hiromu Suzuki; Masafumi Murai; Takefumi Kikuchi; Hiroaki Mita; Fumio Itoh; Jean-Pierre J Issa; Takashi Tokino; Kohzoh Imai
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more
  19 in total

1.  Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancer.

Authors:  Qi Shen; Wanfen Tang; Jie Sun; Lifeng Feng; Hongchuan Jin; Xian Wang
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of β-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.

Authors:  Wenxing Fan; Jie Huang; Hua Xiao
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.

Authors:  Yanning Ma; Yongfang Yue; Min Pan; Jie Sun; Jue Chu; Xiaoying Lin; Wenxia Xu; Lifeng Feng; Yan Chen; Dingwei Chen; Vivian Y Shin; Xian Wang; Hongchuan Jin
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

4.  Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.

Authors:  Ziliang Jin; Weihua Jiang; Feng Jiao; Zhen Guo; Hai Hu; Lei Wang; Liwei Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 5.  HDACs and HDAC Inhibitors in Cancer Development and Therapy.

Authors:  Yixuan Li; Edward Seto
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

6.  Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription.

Authors:  Martina Minisini; Eros Di Giorgio; Emanuela Kerschbamer; Emiliano Dalla; Massimo Faggiani; Elisa Franforte; Franz-Josef Meyer-Almes; Rino Ragno; Lorenzo Antonini; Antonello Mai; Francesco Fiorentino; Dante Rotili; Monica Chinellato; Stefano Perin; Laura Cendron; Christian X Weichenberger; Alessandro Angelini; Claudio Brancolini
Journal:  Nucleic Acids Res       Date:  2022-03-21       Impact factor: 16.971

7.  YY1-MIR372-SQSTM1 regulatory axis in autophagy.

Authors:  Lifeng Feng; Yanning Ma; Jie Sun; Qi Shen; Leiming Liu; Haiqi Lu; Faliang Wang; Yongfang Yue; Jiaqiu Li; Shenjie Zhang; Xiaoying Lin; Jue Chu; Weidong Han; Xian Wang; Hongchuan Jin
Journal:  Autophagy       Date:  2014-06-11       Impact factor: 16.016

Review 8.  Histone deacetylase inhibitors and cell death.

Authors:  Jing Zhang; Qing Zhong
Journal:  Cell Mol Life Sci       Date:  2014-06-05       Impact factor: 9.261

9.  Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.

Authors:  Geoffrey M Matthews; Parinaz Mehdipour; Leonie A Cluse; Katrina J Falkenberg; Eric Wang; Mareike Roth; Fabio Santoro; Eva Vidacs; Kym Stanley; Colin M House; James R Rusche; Christopher R Vakoc; Johannes Zuber; Saverio Minucci; Ricky W Johnstone
Journal:  Blood       Date:  2015-10-07       Impact factor: 22.113

10.  Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.

Authors:  Nichola Cruickshanks; Hossein A Hamed; Laurence Booth; Seyedmehrad Tavallai; Jahangir Syed; Gangadharan B Sajithlal; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-08-22       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.